Sanofi’s Adacel Tdap Vaccine Receives Broader Approval Than GSK’s Boostrix

Sanofi-Aventis' postmarketing commitments for Adacel include a 16,000-patient epidemiologic safety surveillance study of the tetanus, diphtheria and acellular pertussis vaccine